PDCD1 and non-small cell lung carcinoma: Consistent with the current knowledge of the PD-1/PD-L1 blockade’s mechanism of action, PD-L1 expression was the first response biomarker developed, and, so far, the most successful guiding treatment choice in locally advanced and metastatic non-oncogene addicted NSCLC [6,23].